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Background: The anticancer properties of aspirin are restricted by its gastrointestinal toxicity and its limited
efficacy. Therefore, we synthesized phospho-aspirin (PA-2; MDC-22), a novel derivative of aspirin, and evaluated its
chemotherapeutic and chemopreventive efficacy in preclinical models of triple negative breast cancer (TNBC).
Methods: Efficacy of PA-2 was evaluated in human breast cancer cells in vitro, and in orthotopic and subcutaneous
TNBC xenografts in nude mice. Mechanistic studies were also carried out to elucidate the mechanism of action of
PA-2.
Results: PA-2 inhibited the growth of TNBC cells in vitro more potently than aspirin. Treatment of established
subcutaneous TNBC xenografts (MDA-MB-231 and BT-20) with PA-2 induced a strong growth inhibitory effect,
resulting in tumor stasis (79% and 90% inhibition, respectively). PA-2, but not aspirin, significantly prevented
the development of orthotopic MDA-MB-231 xenografts (62% inhibition). Mechanistically, PA-2: 1) inhibited the
activation of epidermal growth factor receptor (EGFR) and suppressed its downstream signaling cascades,
including PI3K/AKT/mTOR and STAT3; 2) induced acetylation of p53 at multiple lysine residues and enhanced
its DNA binding activity, leading to cell cycle arrest; and 3) induced oxidative stress by suppressing the
thioredoxin system, consequently inhibiting the activation of the redox sensitive transcription factor NF-κB.
These molecular alterations were observed in vitro and in vivo, demonstrating their relevance to the anticancer
effect of PA-2.
Conclusions: Our findings demonstrate that PA-2 possesses potent chemotherapeutic efficacy against TNBC,
and is also effective in its chemoprevention, warranting further evaluation as an anticancer agent.
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Breast cancer is the second most common cause of fe-
male cancer-related deaths, with more than one mil-
lion new cases diagnosed per year throughout the
world [1]. Despite advances in its early detection,
breast cancer remains a significant health problem. In
particular, triple negative breast cancer (TNBC) is
known to be more aggressive with poor prognosis, and
is frequently associated with resistance to chemother-
apeutic agents. Thus, novel agents capable of inhibit-
ing TNBC are urgently needed.
Aspirin, a prototypical non-steroidal anti-inflammatory
drug (NSAID), is the most widely used anti-inflammatory
medication in the world [2,3]. NSAIDs have a signifi-
cant antineoplastic effect, which should be viewed, at
least in part, in the context of the increasingly appre-
ciated role of inflammation in cancer. Aspirin has
been formally documented to be a chemopreventive
agent against colon cancer [4,5]. Epidemiological stud-
ies also support a role of aspirin in reducing the risk
of breast cancer [6]. However, gastrointestinal toxicity
caused by chronic aspirin use is a significant health
concern. In order to reduce the toxicity and enhance
the efficacy of aspirin, we synthesized phospho-aspirin
(PA-2; MDC-22; Figure 1A), which consists of aspirin
chemically modified at its –COOH group, the moiety
accounting for its gastrointestinal toxicity [7,8]. In-
deed, as we have recently reported, the gastrointestinal
toxicity of PA-2 in rats is much reduced compared to
that of aspirin [9].
The epidermal growth factor receptor (EGFR) and
p53 are key molecular determinants of TNBC [10-12].
Aberrant activation of EGFR plays an important role in
breast carcinogenesis via the sustained initiation of
downstream cascades that promote cell survival and
proliferation. Thus, EGFR is an attractive target for the
development of cancer therapeutics [13]. On the other
hand, the inactivation of p53, a potent tumor suppres-
sor, is also a major contributor to breast cancer develop-
ment [12]. Apart from its ability to block cell cycle
progression and promote apoptosis, it is now appreci-
ated that p53 also suppresses tumor development by
modulating autophagy, cellular metabolism, angiogen-
esis, and metastasis [14]. This portends that the restor-
ation of p53 function in tumors will be extremely
beneficial, since it will not merely inhibit the growth of
tumor cells but also obliterate the microenvironment
required for tumor survival.
Herein, we examined the antineoplastic properties of
PA-2 in TNBC in vitro and in vivo. PA-2 was much
more potent than aspirin in inhibiting the growth of
TNBC cells and strongly suppressed TNBC growth in
subcutaneous and orthotopic xenograft models. Mech-
anistically, the antineoplastic effect of PA-2 is mediatedthrough inhibition of EGFR, acetylation of p53 and in-
duction of oxidative stress.
Methods
Reagents
PA-2 was provided by Medicon Pharmaceuticals, Inc.,
Setauket, NY. Aspirin were purchased from Sigma (St
Louis, MO). For cell culture study, we prepared 500 mM
stock solutions of both in DMSO. In all cell culture
media, the final DMSO concentration was adjusted to
1%. All general solvents and reagents were of HPLC
grade or of the highest grade commercially available.
Antibodies against β-actin were from Sigma. All other
antibodies were from Cell Signaling (Beverly, MA).Cell culture
We used three human breast cancer cell lines: MDA-
MB 231 (ER-, PR-, HER2/Neu-, EGFR+, and p53 mutant
R280K), BT-20 ( ER-, PR-, HER2/Neu-, EGFR++, and
p53 mutant K132G), and MDA-MB-468 (ER-, PR-,
HER2/Neu-, EGFR++, and p53 mutant R2073H). All
were obtained from the American Type Culture Collec-
tion (ATCC, Manassas, VA, and grown as monolayers in
the specific medium and conditions suggested by
ATCC. All cell lines were grown in our laboratory less
than 6 months after their receipt and the cells studied
were between passages 2-10.
Cell viability assay
We used an assay based on reduction of 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
dye (MTT), which was determined according to the
manufacturer’s protocol (Promega, Madison, WI).Cytokinetic analysis
For apoptosis, cells were seeded and treated with PA-2
for 24 h, trypsinized and stained with Annexin V-FITC
(100X dilution; Invitrogen, Carlsbad, CA) and PI (0.5
μg/ml; Sigma, St Louis, MO), then analyzed by FACS-
caliber (BD Biosciences, San Jose, CA). To determine
cell proliferation, we measured the incorporation of 5-
bromo-2′-deoxyuridine (BrdU) into newly synthesized
cellular DNA followed by the manufacture’s protocol
(BD Biosciences), and cells were subjected to flow cyto-
metric analysis. Cell cycle phase distribution was ana-
lyzed by flow cytometry as described [15].Plasmid and siRNA transfection
EGFR, and SIRT1 plasmids were purchased from
Addgene (Cambridge, MA). Transient transfection
was performed with Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) following the manufacturer’s instructions.
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Figure 1 Phospho-aspirin-2 inhibits the growth of TNBC cells. A: Left: Chemical structure of phospho-aspirin-2 (PA-2, MDC-22). Right:
24 h-IC50 values of PA-2 and aspirin in TNBC cell lines. B: MDA-MB-231 and BT-20 cells were treated with PA-2 for 24 h and the percentage of
proliferating cells was determined by BrdU incorporation. C: MDA-MB-231 and BT-20 cells treated with PA-2 for 24 h were stained with Annexin
V/PI, and the percentage of apoptotic cells was determined by flow cytometry. D: PA-2 blocks the G1/S cell cycle phase transition after 24 h
treatment in MDA-MB-231 cells, determined by flow cytometry following PI staining.
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http://www.biomedcentral.com/1471-2407/14/141Determination of reactive oxygen and nitrogen species
(RONS)
After the indicated treatment, cells were collected by
trypsinization, resuspended in 10 μM of 5-(and-6)-
carboxy-2′,7′-dichlorodihydrofluorescein diacetate
(H2DCFDA Invitrogen), or MitoSox Red (Invitrogen)
or dihydroethidium (DHE, Sigma), incubated at 37°C
for 30 min in the dark and their fluorescence inten-
sity was determined by flow cytometry.Urinary F2 isoprostane assay
Urine was collected at the endpoint of treatment. Levels
of F2 isoprostane and creatinine in urine were deter-
mined by ELISA (Oxford Biomedical Research, MA). F2-
isoprostane values were normalized to creatinine levels.
Determination of TrxR reductase activity
After treatment, cells were lysed and TrxR activity was
determined in the protein lysate using a commercially
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turer (Cayman Chemical, Ann Arbor, MI). In this assay,
TrxR uses NADPH to reduce 5,5′-dithiobis-(2-nitro-
benzoic acid) to 5-thio-2-nitrobenzoic acid (TNB).
Glutathione (oxidized and reduced) was determined by
the glutathione (GSH) reductase-coupled 5,5′-dithiobis
(2-nitrobenzoic acid) assay [16].
Immunoblotting
After treatment with PA-2 as indicated, cells were
scraped on ice, washed with ice-cold PBS and lysed in
RIPA lysis buffer (Sigma). Protein concentration was de-
termined using the Bradford method (Bio-Rad, Hercules,
CA). Electrophoresis of cell lysates were performed on
10% SDS-polyacrylamide gel electrophoresis gels and
protein was transferred onto nitrocellulose membranes
as described [17];
Electrophoretic Mobility Shift Assay (EMSA)
Following treatment, nuclear fractions were isolated
from 2 × 106 cells as described [16]. NF-κB, or p53
EMSA was performed according to The Thermo Scien-
tific LightShift Chemiluminescent EMSA Kit (Rockford,
IL) following the instructions of the manufacturer.
Efficacy studies in nude mouse breast xenografts and
orthotopic model
All animal experiments were approved by the Institu-
tional Animal Care and Use Committee.
Treatment protocol
Female Balb/C nude mice (Charles River Laboratories,
Wilmington, MA) were inoculated subcutaneously into
each of their flanks with 2.5-3 × 106 TNBC cells (MDA-
MB-231 or BT-20) in Matrigel (BD Biosciences, Franklin
Lakes, NJ). When the tumor reached approximately 100-
150 mm3, animals were randomized into the control and
treatment groups (n = 10/group). For MDA-MB-231
xenografts, the animals were treated with vehicle or PA-
2 120 mg/kg p.o. in corn oil 5 times/wk. For BT-20 xe-
nografts, animals were treated with vehicle or PA-2 300
mg/kg i.p. in corn oil 5 times/wk.
Prevention protocol
Female Balb/C nude mice were treated with PA-2 120
mg/kg or ASA 40 mg/kg p.o. in corn oil (equimolar) for
1 wk. Then, the mice were inoculated into the mammary
fat pad with 1.0 × 106 MDA-MB-231 cells in Matrigel.
Drug treatment was continued until the end of the
study. Tumor volume was calculated as [length × width
× (length + width/2) × 0.56]. At the end of treatment,
animals were sacrificed and tumors were removed and
weighed. To calculate tumor growth inhibition, we sub-
tracted the baseline tumor volume from the final one.Immunohistochemical analysis
Immunohistochemical staining for Ki-67, Dmp1 and
phospho-NF-κB (p-p65, activated form of NF-κB) was
performed on human breast xenograft tissue samples
as previously described [18]. Apoptosis was deter-
mined by the terminal deoxynucleotidyl transferase-
mediated deoxyuridine triphosphate-biotin nick end-
labeling (TUNEL) assay [19].
Statistical analysis
Results are expressed as mean ± SEM. Differences be-
tween groups were determined by one-factor analysis of
variance followed by Tukey’s test for multiple compari-
sons. p < 0.05 was statistically significant.
Results
PA-2 inhibits the growth of human TNBC through a
strong cytokinetic effect
We first compared the growth inhibitory effect of PA-2
and aspirin in a panel of TNBC cell lines. PA-2 inhibited
cell growth more potently than aspirin in all the cell
lines evaluated. The potency enhancement ranged be-
tween 5 and 7-fold in MDA-MB-231, MDA-MB-468,
and BT-20 (Figure1A). PA-2 inhibited TNBC cell growth
via a triple cytokinetic effect. In MDA-MB-231 and BT-
20 cells, PA-2 a) inhibited cell proliferation by > 40% at
0.5 × IC50 and by > 80% at 1 × IC50; b) induced apop-
tosis by 1.6- to 12-fold over control at 1.5-and 2 × IC50;
and c) suppressed the G1 to S cell cycle phase transition,
leading to accumulation of cells in G1 phase by 14% at
0.5 × IC50 (Figure1B-D).
To assess the efficacy of PA-2 in vivo, we employed
both subcutaneous and orthotopic TNBC xenografts in
nude mice. Initially, we evaluated the chemotherapeutic
effect of PA-2 on subcutaneous MDA-MB-231 and BT-
20 xenografts. As shown in Figure 2A, PA-2 signifi-
cantly inhibited MDA-MB-231 xenograft growth start-
ing on day 8 of treatment until the end of the study (p
< 0.001). At sacrifice, the tumor volume of vehicle was
309 ± 36 mm3 and that of PA-2 was 143 ± 16 mm3,
representing a 79% tumor growth inhibition (p < 0.01).
PA-2 also suppressed the growth of BT-20 xenografts
(Figure 2B). After 28 days of treatment, the tumor vol-
ume of vehicle and PA-2 groups were 248 ± 27 mm3 and
157 ± 15 mm3, respectively (90% inhibition, p < 0.01).
We next evaluated the chemopreventive effect of PA-2
and compared it to aspirin, its parent compound. Fol-
lowing a prevention protocol, we treated nude mice
bearing orthotopically implanted MDA-MB-231 xeno-
grafts with equimolar doses of PA-2 or aspirin starting
1 week before tumor implantation. On day 66 post-
implantation, PA-2 inhibited the development of pri-
mary tumor in the mammary fat pads by 62% (p < 0.05;
Figure 2C). In contrast, aspirin had no significant effect
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Figure 2 Phospho-aspirin-2 inhibits the growth of TNBC xenografts. A: Chemotherapeutic effect of PA-2 on subcutaneous MDA-MB-231
xenografts in nude mice. Two representative tumors from each group are shown. *, p < 0.001, compared to vehicle; n = 10-16 tumors/group.
B: Chemotherapeutic effect of PA-2 on subcutaneous BT-20 xenografts in nude mice. *, p < 0.01, compared to vehicle; n = 10-16 tumors/
group. C: Chemopreventive effect of PA-2. Nude mice bearing orthotopic xenografts of MDA-MB-231 cells were treated with PA-2 or aspirin
for 9 wks, starting 1 wk before cell implantation. The tumor volumes of the orthotopic MDA-MB-231 xenografts at sacrifice were determined
by luciferase in vivo imaging as described in the methods section. Representative tumors from each group are shown. *, p < 0.05, compared
to vehicle. D: Cytokinetic effect of PA-2 in MDA-MB-231 xenografts (treatment protocol). Left: Representative images (top) and the
quantification (bottom) of Ki-67 expression in tumor sections, * p < 0.01. Right: Representative images (top) and the quantification (bottom)
of TUNEL positive cells in tumor sections, * p < 0.002. All values are mean ± SEM.
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http://www.biomedcentral.com/1471-2407/14/141on breast tumor growth in this orthotopic model, con-
sistent with previous findings [20].
We also determined cell proliferation and apoptosis
in MDA-MB-231 xenografts in the treatment study
(Figure 2A) using Ki-67 staining and TUNEL assay,respectively (Figure 2D). Compared to the vehicle, PA-2
inhibited cell proliferation by 44% (p < 0.01) and in-
creased apoptosis by 3-fold (p < 0.002). This indicates
that PA-2 also exerted a cytokinetic effect on TNBC xe-
nografts in vivo.
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http://www.biomedcentral.com/1471-2407/14/141PA-2 modulates the phosphorylation status of EGFR, p53
and NF-κB
To elucidate the mechanisms of action of PA-2, we per-
formed antibody microarray analyses (Kinexus, Vancou-
ver, Canada) on MDA-MB-231 cells treated with vehicle
or PA-2 1.5 × IC50 for 2 h. This assay revealed pro-
nounced changes in EGFR, p53 and NF-κB pathways
following PA-2 treatment (Additional file 1: Table S1).A
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http://www.biomedcentral.com/1471-2407/14/141manner, being evident as early as 1 h after treatment
(Figure 3A). This observation was confirmed in vivo,
where PA-2 reduced EGFR phosphorylation by 68%
and 83% in MDA-MB-231 and BT-20 xenografts, re-
spectively, compared to controls (p < 0.05, Figure 3A).
To determine the role of EGFR inhibition in the anti-
cancer effect of PA-2, we transiently transfected MDA-
MB-231 cells with an EGFR-overexpressing plasmid,
and evaluated whether PA-2-induced cell death was af-
fected. EGFR overexpression and activation of its
downstream target p-PI3K was confirmed by western
blot (Figure 3B). EGFR overexpression suppressed theA
B
C
Figure 4 Phospho-aspirin-2 inhibits EGFR downstream signaling. A. P
BT-20 cells in a time-dependent manner. B: PA-2 treatment resulted in the
time-dependent reduction of the expression of p-PI3K, p-Akt, p-mTOR, p-p7
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were performed with β-actin as loading control.induction of apoptosis by PA-2. Compared to mock
transfected control, EGFR-overexpressing MDA-MB-
231 cells have 2.5-fold reduction in the annexin V (+)
fraction after treatment with PA-2 2xIC50 (Figure 3B).
This indicates that EGFR inhibition is an important
mechanism of action of PA-2, and the reversal of this
effect mediates drug resistance.
An important upstream regulator of EGFR phosphor-
ylation is ADAM17, which activates EGFR through a lig-
and cleavage mechanism [21]. We assessed the effect of
PA-2 on ADAM proteins. As shown in Figure 2C, in
MDA-MB231 and BT-20 cells, PA-2 reduced theA-2 1.5 × IC50 inhibited STAT3 phosphorylation in MDA-MB-231 and
sequential inactivation of PI3K signaling cascade, as indicated by the
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http://www.biomedcentral.com/1471-2407/14/141expression of ADAM17. Moreover, PA-2 suppressed the
levels of ADAM17 in MDA-MB-231 orthotopic
xenografts.
Inhibition of EGFR activation resulted in a potent in-
hibitory effect on its downstream signaling cascades,
STAT3 and PI3K/Akt pathways. PA-2 reduced STAT3
phosphorylation in MDA-MB-231 and BT-20 cells (Fig-
ure 4A). PA-2 also suppressed the levels of p-PI3K and
p-Akt in these cells in vitro (Figure 4B) and in MDA-
MB-231 xenografts (Figure 4C). In addition, the down-
stream targets of PI3K/Akt pathway, including p-mTOR,
p-4E-BP1 and p-70S6K1, were reduced after prolonged
(16h) PA-2 treatment (Figure 4B). Hence, PA-2 triggered
a temporal suppression of EGFR signaling cascades in
TNBC.
PA-2 induces acetylation of p53 and cell cycle arrest
The tumor suppressor gene p53 is frequently inacti-
vated in TNBC [22]. In MDA-MB-231 and BT-20
cells, PA-2 enhanced the DNA-binding activity of p53
in a concentration-dependent manner (Figure 5A).
PA-2 did not appear to alter the nuclear shuttling of
p53 (Figure 5A). On the other hand, immunoprecipi-
tation showed that PA-2 significantly reduced thebinding of p53 to murine double minute 2 (MDM2)
(Figure 5B). Dissociation of p53 from MDM2, which
otherwise binds to p53 and represses its transcrip-
tional activity [23], may therefore contribute to the in-
duction of p53 DNA binding activity by PA-2 in
TNBC cells. The activation of p53 by PA-2 was conse-
quential, as PA-2 blocked G1 to S cell cycle transition
(Figure 1D) and up-regulated p21 in TNBC cells in vi-
tro and in MDA-MB-231 xenografts (Figure 5C).
Acetylation of p53 at lysine residues is critical for
its stability and transcriptional activity [24]. Given
that the aspirin moiety of PA-2 contains an acetyl
group capable of acetylating multiple proteins in can-
cer cells [25], we examined the effect of PA-2 on the
acetylation status of p53. In MDA-MB-231 cells, PA-
2 induced p53 acetylation at three distinct lysine resi-
dues (K373, K379 and K382) in a time-dependent
manner; while in BT-20 cells PA-2 induced acetyl-
ation at K373 and K379 residues (Figure 6A). In
MDA-MB-231 and BT-20 xenografts, treatment with
PA-2 increased p53 acetylation at K382 and K373 res-
idues, respectively (Figure 6A).
To further assess the role of p53 acetylation in cell
death induction by PA-2, we overexpressed in MDA-
AB
C
Figure 6 Phospho-aspirin-2 induces p53 acetylation and Dmp1 expression. A: Upper: PA-2 induced the acetylation of p53 in MDA-MB-231
(K373, K379 and K382) and BT-20 (K373 and K379) cells. Lower: PA-2 induced p53 acetylation in MDA-MB-231 (K382) and BT-20 (K373) xenografts.
B: Left panel: SIRT1 overexpression prevents p53 acetylation (K382) by PA-2. Right panel: SIRT1 overexpression attenuated PA-2-induced apoptosis
in MDA-MB-231 cells. Western blot confirmed the overexpression of SIRT1. C: Upper: PA-2 1.5 x IC50 increased the expression of Dmp1 in MDA-
MB-231 and BT-20 cells. Lower: PA-2 increased Dmp1 expression in xenografts, as indicated by western blot (left) and immunohistochemistry
(right). Two representative tissue sections are shown. *, p < 0.02, compared to control; magnification 200X. Immunoblots were performed with β-
actin as the loading control.
Huang et al. BMC Cancer 2014, 14:141 Page 9 of 14
http://www.biomedcentral.com/1471-2407/14/141MB-231 cells SIRT1, which negatively regulates p53
through its de-acetylation [26,27]. Overexpression of
SIRT1 blocked the ability of PA-2 to acetylate p53 at
the K382 residue (Figure 6B). Importantly, SIRT1
overexpression attenuated the induction of apoptosis
in response to PA-2 by 71%, indicating that PA-2 in-
duces apoptosis, at least in part, by a p53 acetylation-
dependent mechanism (Figure 6B).PA-2 may also regulate p53 independently of acetyl-
ation. PA-2 significantly enhanced the expression of
Dmp1, a tumor suppressor that induces p53-dependent
cell cycle arrest by directly binding to its promoter [28].
Such an effect is observed in TNBC cells in vitro. In
MDA-MB-231 xenografts, PA-2 treatment increased
Dmp1 expression by 57% (p < 0.02) compared to the
control group (Figure 6C).
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Figure 7 Phospho-aspirin-2 induces oxidative stress in TNBC. A: PA-2 induced RONS in MDA-MB-231 and BT-20 cells after 1h treatment,
as determined by DCFDA, DHE and MitoSOX Red staining and flow cytometry. B: Left panel: GSH level was suppressed in MDA-MB-231 cells
treated with various concentrations of PA-2 for 24 h, BSO as a positive control. Values are mean ± SEM. Middle panel: PA-2 and BSO
synergistically induced RONS. RONS production was determined by DCFDA staining in MDA-MB-231 cells treated with PA-2 or PA-2 plus
BSO for 1 h. Right panel: PA-2 and BSO synergistically inhibited cell growth. Cell growth inhibition was determined by MTT in MDA-MB-231
cells treated with PA-2 or PA-2 plus BSO for 24h. C: PA-2 increased the levels of 15-F2t-Isoprostane in 24-h urine from nude mice bearing
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RONS play a significant role in the action of phospho-
NSAIDs [29]. We determined the effect of PA-2 using
various molecular probes: DCFDA (general RONS),
DHE (cytoplasmic O2•
−), and MitoSOX Red (mito-
chondrial O2•
−). Compared to control, PA-2 1.5 ×
IC50 increased DCFDA by 76%, DHE by 51% and
MitoSOX Red by 51% in MDA-MB-231 cells (Fig-
ure 7A). N-acetylcysteine (10 mM), a ROS scavenger,
partly blocked ROS induction by 26% in MDA-MB-
231 cells (Figure 7A). In BT-20 cells, PA-2 increased
MitoSOX Red by 25%. PA-2 1-1.5 × IC50 also decreased
the level of glutathione, a major cellular antioxidant.
Co-incubation of PA-2 with BSO, an inhibitor of GSH
synthesis, synergistically induced RONS levels and
inhibited cell growth (Figure 7B).To assess the effect of PA-2 on RONS in vivo, we
measured urinary 15-F2t-isoprostane, a marker of
oxidative stress [30,31], in the mice bearing TNBC
xenografts. In orthotopic MDA-MB-231 xenografts
(Figure 2C), 15-F2t-isoprostane levels on day 25 were
28.7 ± 3.3 ng/mg creatinine in controls and 40.9 ± 2.2
ng/mg creatinine in the PA-2 group, representing a
nearly 40% increase (p < 0.05) (Figure 7C). In contrast,
aspirin had no significant effect (p = 0.6). In BT-20 xe-
nografts, PA-2 treatment increased 15-F2t-isoprostane
levels by over 3-fold over the control (p < 0.006).
Hence, PA-2, but not aspirin, induced RONS in vivo.
The thioredoxin (Trx) system, composed of thiore-
doxin reductase (TrxR) and Trx-1, plays an important
role in redox homeostasis by reducing oxidized pro-
teins; the latter is overexpressed in TNBC [32]. PA-2
inhibited TrxR activity in MDA-MB-231 cells in cell
AB
Figure 8 Phospho-aspirin-2 suppresses the thioredoxin (Trx) system and activation of NF-кB. A: Left panel: PA-2 1.5 × IC50 reduced TrxR
activity in MDA-MB-231 cells after 1 h treatment. *, p < 0.02, compared to control. Immunoblots of TrxR and Trx-1 showed that PA-2 reduced
the expression of Trx-1 in MDA-MB-231 cells. Right panel: PA-2 reduced TrxR activity in the protein lysates from MDA-MB-231 xenografts
(treatment protocol) from animals treated with vehicle or PA-2 for 25 days. *, p < 0.04, compared to vehicle. B: Left panel: PA-2 inhibited
constitutive NF-κB activation. EMSA for NF-κB of nuclear fractions isolated from MDA-MB-231 (upper) and BT-20 (lower) cells after 4 h treatment
with or without PA-2 1.5 × IC50. To determine the specificity of the NF-κB transcription factor-DNA complex, the control nuclear fraction was
incubated in the presence of 100-fold molar excess of unlabeled oligonucleotide containing the consensus sequence for either the specific
(+NF-κB) or an unspecific (+AP-1) transcription factor. Right panel: NF-κB (p-p65) levels from MDA-MB-231 tumors, determined by
immunohistochemistry using an anti-p-p65 antibody, were reduced in PA-2 treated group compared to the vehicle control. The percentage
of p-p65-positive cells in various fields was determined and averaged for each xenograft. *, p < 0.0009, compared to vehicle. Representative
images are shown; magnification 200X. All values are mean ± SEM.
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41%, respectively (p < 0.02-0.04), without affecting its
levels (Figure 8A). PA-2 also significantly reduced
Trx-1 levels in MDA-MB-231 cells after 1h treatment
with 1.5 × IC50 PA-2 (Figure 8A). These results indi-
cate that PA-2 targets major components of the Trx
system.
The Trx system is closely linked with the NF-κB sig-
naling pathway. Trx-1 enhances DNA binding of NF-κB
by reducing the intermolecular Cys62 -S-S- bond of its
p50 subunit [33]. We thus examined the effect on PA-2
on NF-κB activation. Consistent with its inhibitory ef-
fect on Trx-1 expression, PA-2 also inhibited NF-κB-
DNA binding in a concentration-dependent manner in
MDA-MB-231 and BT-20 cells (Figure 8B). A similar in-
hibition was observed in MDA-MB-231 xenografts. PA-
2 reduced the levels of activated p-p65 by 44% (p <
0.009), compared to the control group (Figure 8B).Discussion
Our data demonstrate that PA-2, a novel derivative of
aspirin, effectively inhibits TNBC in preclinical models
and is much more potent than aspirin, its parent com-
pound. The anticancer activity of PA-2 is associated
with a pronounced effect on a) EGFR activation; b) p53
acetylation and c) RONS induction. These signaling ef-
fects of PA-2 culminate in the substantial inhibition of
cell proliferation and induction of apoptosis, the net ef-
fect of which is a strong reduction in TNBC xenograft
growth in vivo.
Efficacy and safety are the prime considerations in
the evaluation of anticancer agents [34], and the latter
is especially paramount in chemoprevention. Extensive
epidemiological and clinical evidence supports a benefi-
cial role of aspirin in the prevention of breast, colon,
and lung cancers [35]; however, its gastrointestinal tox-
icity is limiting. Our results demonstrated that PA-2,
p21
p53 acetylation EGFR 
PI3K
Akt
mTOR
p70S6K
apoptosis proliferation
ROS
TRIPLE NEGATIVE BREAST CANCER
PA-2 (MDC-22)
Trx-1/TrxR
NF-kB
STAT3
G1/S
Figure 9 Proposed mechanism for the anticancer effect of
phospho-aspirin-2 in TNBC. PA-2 inhibits TNBC through (i)
inhibition of EGFR phosphorylation and attenuation of downstream
signaling cascades (STAT3 and PI3K/Akt); (ii) acetylation of p53,
which enhances p53 DNA-binding activity, p21 expression and cell
cycle arrest; and (iii) induction of oxidative stress and alteration of
the Trx system; which culminate in the inhibition of cell proliferation
and induction of apoptosis in TNBC.
Huang et al. BMC Cancer 2014, 14:141 Page 12 of 14
http://www.biomedcentral.com/1471-2407/14/141with the novel phospho-modification, is superior to as-
pirin both in terms of efficacy in TNBC, as well as
safety [9]. PA-2, but not aspirin, administered in a che-
moprevention protocol slowed the development of
orthotopic MDA-MB-231 xenografts.
PA-2 is highly efficacious when used in the treat-
ment setting and its chemotherapeutic effect is even
stronger than its chemopreventive effect. PA-2 po-
tently inhibits TNBC in vivo, almost completely ar-
resting the growth of both MDA-MB-231 and BT-20
xenografts. Consistent with its strong chemotherapeu-
tic efficacy, PA-2 induced a profound cytokinetic ef-
fect involving inhibition of cell proliferation and
induction of apoptosis. Hence, PA-2 is a promising an-
ticancer candidate that merits further evaluation.
Our work identified EGFR, p53 and RONS as the
major signaling mechanisms (Figure 9) involved in eli-
citing the growth inhibitory effect of PA-2. EGFR is
overexpressed in 16–48% of breast cancers and its ex-
pression is associated with poor prognosis [36,37]. In
particular, EGFR is frequently overexpressed in TNBC,
a subset of breast cancer that is characterized by their
unique molecular profile, aggressive behavior and dis-
tinct patterns of metastasis [38]. PA-2 is an inhibitor
of EGFR phosphorylation in vitro and in vivo. The in-
hibitory effect of PA-2 appears to be mediated by anovel mechanism involving the inhibition of
ADAM17, a major protease that controls availability
of EGFR ligands [39]. A key consequence of PA-2-
induced inhibition of EGFR is the suppression of pro-
survival STAT3 and PI3K and the sequential inactiva-
tion of their downstream signaling propagation, thereby
causing growth inhibition and cell death.
Mutations of p53 are exceptionally frequent in TNBC
(>80%) and its inactivation predicts poor survival in
TNBC patients [10,12]. Activation-inactivation of p53
depends on a repertoire of post-translational modifica-
tions [40], including phosphorylation and acetylation.
p53 acetylation was found to be indispensable for its
activation, as it destabilizes the p53-MDM2 interaction,
thereby abrogating MDM2-mediated transcription re-
pression [24]. Here, we show that PA-2 acetylates p53
in vitro and in vivo and disrupts its association with
MDM2, which in turn, enhances p53-DNA binding ac-
tivity. Forced deacetylation of p53 partly attenuated cell
death induction by PA-2, indicating an important role
of p53 acetylation in mediating the effect of PA-2. PA-2
additionally regulates p53 independently of acetylation.
Dmp1 is a transcription factor that physically interacts
with p53 [41]. Dmp1-p53 binding antagonizes the ubi-
quitination of p53 byMDM-2 and promotes the nuclear
translocation of p53 [28]. PA-2 enhanced the expres-
sion of Dmp1 in TNBC cells and in xenografts, which
may further contribute to the robust p53 activation
triggered by PA-2.
The induction of oxidative stress plays a key role in
the anticancer effect of structurally related phospho-
NSAIDs [9,42]. PA-2 induces oxidative stress in TNBC
cells in culture and in xenografts by compromising cel-
lular antioxidant defense mechanisms. First, PA-2 sup-
pressed the Trx system, with both TrxR and Trx-1
affected in a significant way. TrxR and Trx-1 are crit-
ical components of the cellular redox system [43]. Trx-
1 reduces client proteins oxidized by RONS, with itself
undergoing oxidation, while TrxR regenerates the re-
duced Trx-1. In TNBC cells and xenografts, PA-2
inhibited TrxR activity and decreased the expression of
Trx-1. Second, PA-2 significantly reduced intracellular
levels of GSH, the major chemical antioxidant of mam-
malian cells. Induction of oxidative stress has major re-
percussions on redox- and Trx-dependent signaling
cascades, as exemplified by the inhibitory effect on NF-
кB. NF-кB is constitutively active in TNBC [44], and its
aberrant activation is linked to inflammation and can-
cer. Induction of oxidative stress and the subsequent
inhibition of NF-кB by PA-2 may mediate part of its
growth inhibitory effect.
It is of interest that PA-2 has superior efficacy com-
pared to conventional aspirin, the starting compound
for its synthesis. The reasons for this difference are
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expected to have distinct properties from its parent
compound. Perhaps the most relevant property of
these two compounds is their ability to induce oxidative
stress, an effect that accounts for much of the antican-
cer efficacy of phospho-NSAIDs, including phospho-
aspirin [29]. Indeed, PA-2 caused robust oxidative
stress in mice, reflected in enhanced urinary levels of
the biomarker F2-isoprostane. In contrast, aspirin failed
to produce such an effect, and this difference explains
to a large extent their differential efficacy. Additional
mechanistic differences might also contribute, espe-
cially with regards to effects on cell signaling cascades.
Conclusions
Our work indicates that PA-2 possesses chemotherapeu-
tic and chemopreventive efficacy against TNBC in pre-
clinical models, and establishes inhibition of EGFR,
acetylation of p53 and induction of oxidative stress as
critical mediators of its mechanism of action (Figure 9).
The multi-targeted nature of PA-2 towards the dysregu-
lated signaling cascades in TNBC further suggests the
notion that PA-2 may be a promising therapeutic option,
either alone or in combination with other therapies.
Additional file
Additional file 1: Table S1. Antibody microarray analysis on
phosphor-aspirin treated MDA-MB-231 cells. TNBC MDA-MB-231 cells
treated with vehicle or PA-2 1.5 × IC50 for 2 h were performed antibody
microarray analysis by Kinexus (Vancouver, CA).
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